Dr. Maja Zorec

Dr. Maja Zorec is a consultant medical oncologist at Institute of Oncology Ljubljana, Slovenia's national cancer centre and one of Central Europe's leading dedicated oncology institutions. With 15 years of specialist experience and a PhD, she specialises in breast oncology, immunotherapy, and precision oncology. Institute of Oncology Ljubljana is a OECI (Organisation of European Cancer Institutes) designated comprehensive cancer centre, providing multidisciplinary cancer care to national and international patients to the highest European standards. Dr. Zorec's expertise in breast cancer treatment and precision oncology — including molecular profiling, targeted therapy, and immune checkpoint inhibition — places her at the forefront of modern cancer medicine in Central Europe.

Dr. Zorec completed her MD at the University of Ljubljana Faculty of Medicine and undertook medical oncology residency and specialist training at Institute of Oncology Ljubljana. She earned her PhD, contributing peer-reviewed research to breast oncology and immunotherapy. Her oncology training encompassed systemic therapy including chemotherapy, endocrine therapy, HER2-targeted therapy, CDK4/6 inhibitors, PARP inhibitors, and immune checkpoint inhibitors for breast and other solid tumours. She has completed advanced training in precision oncology — including molecular tumour board participation and next-generation sequencing interpretation — and immunotherapy toxicity management. She participates in ESMO Congress, SABCS, and Slovenian oncology CME.

Dr. Zorec's oncology practice focuses on breast cancer and the application of precision oncology and immunotherapy across solid tumours. Her breast oncology expertise covers all breast cancer subtypes: hormone receptor-positive (applying CDK4/6 inhibitors such as palbociclib and ribociclib, and endocrine therapy), HER2-positive (applying trastuzumab, pertuzumab, and TDM-1/trastuzumab deruxtecan), and triple-negative breast cancer (applying chemotherapy, PARP inhibitors for BRCA-mutated disease, and pembrolizumab immunotherapy). She participates in the multidisciplinary breast cancer tumour board and manages patients through neoadjuvant, adjuvant, and metastatic treatment phases. Her precision oncology practice involves molecular profiling and actionable mutation identification for personalised treatment selection.

Institute of Oncology Ljubljana is Slovenia's national cancer centre, affiliated with the University of Ljubljana and designated by the Organisation of European Cancer Institutes (OECI) as a comprehensive cancer centre. It attracts patients from across Slovenia and internationally — particularly from the former Yugoslav region and Central Europe — for multidisciplinary oncology care to European standards. Dr. Zorec consults in Slovenian, German, and English. Ljubljana's Jože Pučnik Airport connects to major European hubs. The Institute provides English-language oncology reports and second opinion consultations, and has experience with telemedicine pre-assessment for international patients evaluating treatment options in Ljubljana.

Dr. Zorec has been recognised by the Slovenian Oncological Society and Institute of Oncology Ljubljana for her contributions to breast oncology research and precision medicine. Her PhD from the University of Ljubljana reflects peer-evaluated research contribution to oncology. She has participated in clinical trials through EORTC and Breast International Group (BIG) networks and has contributed to peer-reviewed publications on breast cancer treatment outcomes and immunotherapy in solid tumours. She has been invited to present at ESMO Congress and the San Antonio Breast Cancer Symposium (SABCS), reflecting her international recognition in the breast oncology community.